FY2025 EPS Estimates for Medtronic Raised by William Blair

Medtronic plc (NYSE:MDT - Free Report) - Equities researchers at William Blair raised their FY2025 EPS estimates for shares of Medtronic in a research note issued on Tuesday, February 18th. William Blair analyst M. Andrew now forecasts that the medical technology company will post earnings per share of $5.47 for the year, up from their prior estimate of $5.46. The consensus estimate for Medtronic's current full-year earnings is $5.46 per share. William Blair also issued estimates for Medtronic's Q3 2026 earnings at $1.44 EPS and FY2026 earnings at $5.81 EPS.

Several other analysts have also issued reports on MDT. Sanford C. Bernstein raised their price target on shares of Medtronic from $96.00 to $97.00 and gave the stock an "outperform" rating in a research report on Wednesday, November 20th. Royal Bank of Canada reissued an "outperform" rating and set a $105.00 target price on shares of Medtronic in a research report on Wednesday. Needham & Company LLC reaffirmed a "hold" rating on shares of Medtronic in a report on Wednesday. Robert W. Baird lifted their price objective on Medtronic from $90.00 to $91.00 and gave the stock a "neutral" rating in a report on Wednesday. Finally, UBS Group upped their target price on Medtronic from $85.00 to $95.00 and gave the company a "neutral" rating in a research note on Wednesday. One research analyst has rated the stock with a sell rating, nine have assigned a hold rating, six have given a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat.com, the company currently has a consensus rating of "Hold" and a consensus price target of $95.20.

Medtronic Stock Performance

Shares of Medtronic stock traded up $2.01 during midday trading on Thursday, hitting $89.95. The company had a trading volume of 11,600,480 shares, compared to its average volume of 7,464,932. Medtronic has a 1-year low of $75.96 and a 1-year high of $93.08. The business's 50 day simple moving average is $85.93 and its two-hundred day simple moving average is $87.03. The stock has a market cap of $115.34 billion, a PE ratio of 27.34, a P/E/G ratio of 2.46 and a beta of 0.84. The company has a debt-to-equity ratio of 0.48, a current ratio of 1.90 and a quick ratio of 1.39.

Medtronic (NYSE:MDT - Get Free Report) last announced its earnings results on Tuesday, February 18th. The medical technology company reported $1.39 earnings per share for the quarter, beating the consensus estimate of $1.36 by $0.03. The firm had revenue of $8.29 billion during the quarter, compared to the consensus estimate of $8.33 billion. Medtronic had a return on equity of 14.07% and a net margin of 12.83%.

Institutional Investors Weigh In On Medtronic

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Vanguard Group Inc. increased its stake in shares of Medtronic by 0.6% in the 4th quarter. Vanguard Group Inc. now owns 124,203,387 shares of the medical technology company's stock valued at $9,921,367,000 after acquiring an additional 754,395 shares during the last quarter. State Street Corp increased its stake in Medtronic by 0.9% in the third quarter. State Street Corp now owns 60,731,367 shares of the medical technology company's stock valued at $5,509,155,000 after purchasing an additional 520,027 shares in the last quarter. Capital Research Global Investors raised its holdings in Medtronic by 1.8% in the fourth quarter. Capital Research Global Investors now owns 33,203,685 shares of the medical technology company's stock worth $2,652,310,000 after purchasing an additional 571,700 shares during the period. Geode Capital Management LLC boosted its position in shares of Medtronic by 2.2% during the fourth quarter. Geode Capital Management LLC now owns 27,056,217 shares of the medical technology company's stock worth $2,155,085,000 after purchasing an additional 574,055 shares in the last quarter. Finally, Deutsche Bank AG grew its holdings in shares of Medtronic by 2.1% in the 4th quarter. Deutsche Bank AG now owns 18,443,640 shares of the medical technology company's stock valued at $1,473,278,000 after buying an additional 372,168 shares during the period. Institutional investors own 82.06% of the company's stock.

Insiders Place Their Bets

In other news, EVP Brett A. Wall sold 9,850 shares of the stock in a transaction on Wednesday, January 8th. The stock was sold at an average price of $80.41, for a total value of $792,038.50. Following the transaction, the executive vice president now owns 40,708 shares of the company's stock, valued at $3,273,330.28. This represents a 19.48 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Company insiders own 0.20% of the company's stock.

Medtronic Announces Dividend

The company also recently disclosed a quarterly dividend, which was paid on Friday, January 10th. Investors of record on Friday, December 27th were given a $0.70 dividend. The ex-dividend date of this dividend was Friday, December 27th. This represents a $2.80 dividend on an annualized basis and a yield of 3.11%. Medtronic's payout ratio is 85.11%.

About Medtronic

Medtronic plc develops, manufactures, and sells device-based medical therapies to healthcare systems, physicians, clinicians, and patients worldwide. Its Cardiovascular Portfolio segment offers implantable cardiac pacemakers, cardioverter defibrillators, and cardiac resynchronization therapy devices; cardiac ablation products; insertable cardiac monitor systems; TYRX products; and remote monitoring and patient-centered software.